AU2020212404B2 - Plasminogen for treating and preventing microthrombosis - Google Patents

Plasminogen for treating and preventing microthrombosis

Info

Publication number
AU2020212404B2
AU2020212404B2 AU2020212404A AU2020212404A AU2020212404B2 AU 2020212404 B2 AU2020212404 B2 AU 2020212404B2 AU 2020212404 A AU2020212404 A AU 2020212404A AU 2020212404 A AU2020212404 A AU 2020212404A AU 2020212404 B2 AU2020212404 B2 AU 2020212404B2
Authority
AU
Australia
Prior art keywords
plasminogen
patient
glu
plg
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020212404A
Other languages
English (en)
Other versions
AU2020212404A1 (en
Inventor
Hans-Joachim Anders
Satish Kumar DEVARAPU
Hanne Rieke GERDING
Stephan T. KIESSIG
Marc Mazur
Christoph SCHIMMELPFENNIG
Chongxu SHI
Ricarda Welz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PreviPharma Consulting GmbH
Original Assignee
PreviPharma Consulting GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PreviPharma Consulting GmbH filed Critical PreviPharma Consulting GmbH
Publication of AU2020212404A1 publication Critical patent/AU2020212404A1/en
Application granted granted Critical
Publication of AU2020212404B2 publication Critical patent/AU2020212404B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020212404A 2019-01-24 2020-01-24 Plasminogen for treating and preventing microthrombosis Active AU2020212404B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19153572.3 2019-01-24
EP19153572 2019-01-24
PCT/EP2020/051733 WO2020152322A1 (en) 2019-01-24 2020-01-24 Plasminogen for treating and preventing microthrombosis

Publications (2)

Publication Number Publication Date
AU2020212404A1 AU2020212404A1 (en) 2021-08-26
AU2020212404B2 true AU2020212404B2 (en) 2025-11-27

Family

ID=65234430

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020212404A Active AU2020212404B2 (en) 2019-01-24 2020-01-24 Plasminogen for treating and preventing microthrombosis

Country Status (9)

Country Link
US (1) US20220072110A1 (https=)
EP (1) EP3914288A1 (https=)
JP (1) JP2022518496A (https=)
KR (1) KR20210119428A (https=)
CN (1) CN113597313A (https=)
AU (1) AU2020212404B2 (https=)
BR (1) BR112021014068A2 (https=)
CA (1) CA3127375A1 (https=)
WO (1) WO2020152322A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022258590A1 (en) 2021-06-08 2022-12-15 Previpharma Consulting Gmbh Process for isolating plasminogen from a blood plasma fraction
WO2025132796A1 (en) 2023-12-21 2025-06-26 Previpharma Consulting Gmbh Process for isolating glu-plasminogen from a solution

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115551A (en) * 1973-12-18 1978-09-19 Choay S.A. Compounds of the plasminogen type and method for obtaining such compounds from placental pulps
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency
WO2018162754A1 (en) * 2017-03-09 2018-09-13 Previpharma Consulting Gmbh Preparing and use of glu-plasminogen from blood fractions
EP3395353A1 (en) * 2015-12-18 2018-10-31 Talengen International Limited Method for preventing or treating diabetes mellitus nerve injury and related diseases
EP3395359A1 (en) * 2015-12-18 2018-10-31 Talengen International Limited Method for preventing or treating acute thrombosis and chronic thrombosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DK3391902T5 (da) * 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115551A (en) * 1973-12-18 1978-09-19 Choay S.A. Compounds of the plasminogen type and method for obtaining such compounds from placental pulps
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency
EP3395353A1 (en) * 2015-12-18 2018-10-31 Talengen International Limited Method for preventing or treating diabetes mellitus nerve injury and related diseases
EP3395359A1 (en) * 2015-12-18 2018-10-31 Talengen International Limited Method for preventing or treating acute thrombosis and chronic thrombosis
WO2018162754A1 (en) * 2017-03-09 2018-09-13 Previpharma Consulting Gmbh Preparing and use of glu-plasminogen from blood fractions

Also Published As

Publication number Publication date
WO2020152322A1 (en) 2020-07-30
KR20210119428A (ko) 2021-10-05
JP2022518496A (ja) 2022-03-15
EP3914288A1 (en) 2021-12-01
US20220072110A1 (en) 2022-03-10
CN113597313A (zh) 2021-11-02
AU2020212404A1 (en) 2021-08-26
BR112021014068A2 (pt) 2021-09-21
CA3127375A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
Gold et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
Jansen et al. Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty
McKenna Abnormal coagulation in the postoperative period contributing to excessive bleeding
Sharma et al. Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension
Larsson et al. Valproic acid selectively increases vascular endothelial tissue‐type plasminogen activator production and reduces thrombus formation in the mouse
CN110612350A (zh) 源自血液的谷氨酸-纤溶酶原的制备和使用
Weitz et al. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.
AU2020212404B2 (en) Plasminogen for treating and preventing microthrombosis
US20220184189A1 (en) Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase
AU2014209886B2 (en) Hemostatic compositions
RU2714112C2 (ru) Терапевтическая APAC-молекула, содержащая гепарин, конъюгированный с белком плазмы крови
LeVeen et al. Venous and arterial occlusive disease treated by enzymatic clot lysis
RU2813699C2 (ru) Плазминоген для лечения и профилактики микротромбоза
Soutar et al. Anticoagulant therapy with ancrod
Tai et al. A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency
Le Sache et al. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit
Thalji et al. Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding
Bhagirath et al. Management of bleeding complications in the anticoagulated patient
Cole et al. Ancrod versus heparin for anticoagulation during vascular surgical procedures
Chesterman et al. Thrombolytic therapy with streptokinase
AU2013366544A1 (en) Sealant compositions
CN114096259A (zh) 用于缺血性中风的治疗和二级预防的ld肝素
Giles et al. The thrombogenicity of prothrombin complex concentrates: III. The relationship of in vivo thrombogenicity to the nature of the starting plasma
JP2012519674A (ja) フィブリノーゲンの新規な使用
Sharnoff Prevention of venous thrombosis and pulmonary embolism

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)